A Breast Cancer drug shown to increase the chances of survival for women with the ‘Angelina Jolie gene’ is set to be rejected by the NHS. Studies had shown that olaparib reduced the risk of death by almost a third in women with high-risk, early-stage breast cancer with mutations in the BRCA1 or 2 genes.
A breast cancer drug shown to increase the chances of survival for women with the ‘Jolie gene’ is set to be rejected for use by the NHS.
Studies have shown that olaparib reduces the risk of death by almost a third in women with high-risk, early-stage breast cancer with mutations in the BRCA1 or 2 genes.
But the daily pill was rejected by NICE on the grounds that it is not as cost effective as routine monitoring.
Olaparib, which is taken in tablet form, is already approved as a treatment for some patients with advanced ovarian, breast, prostate and pancreatic cancer.
Experts hailed its approval after trials revealed it was particularly effective against BRCA mutations, exploiting a genetic weakness in cancer cells.
But drugs watchdog NICE said in draft guidelines it would not recommend the treatment for use on the NHS.
Now cancer charities are asking drugmakers AstraZeneca, NICE and NHS England to find a way to prescribe the drug to the hundreds of women who would benefit from it every year.
Baroness Delyth Morgan, chief executive of Breast Cancer Now, said the decision could be a death sentence for some women.
She said: “About 5-10% of women with breast cancer carry an inherited altered gene, of which the BRCA 1 and 2 genes are the most common.
“Unfortunately, some people with high-risk, HER2-negative primary breast cancer with an altered BRCA gene may see their cancer come back after treatment.
“Olaparib has the potential to reduce a patient’s risk of cancer recurring or progressing to incurable secondary breast cancer, and to save people who die from this devastating disease.
“Yet today’s proposed decision robs these patients of the opportunity to receive the best possible treatment and hope for a future without breast cancer.”
The draft guidelines published by NICE said it does not recommend olaparib for adults with high-risk HER2-negative early breast cancer with BRCA1 or 2 mutations who have previously received chemotherapy treatment before or after surgery.
He said the committee appreciated the unmet need for treatment options for these patients and that olaparib was an effective treatment.
Olaparib, which comes in tablet form, is already licensed as a treatment for some patients with advanced ovarian, breast, prostate and pancreatic cancer
However, according to the company’s own analysis, olaparib was not cost-effective compared to routine monitoring, he said.
Andrew Tutt, professor of oncology at King’s College London, said it was a “life-changing drug” for patients diagnosed with this type of hereditary breast cancer at an early stage.
He said: “Today’s decision is a missed opportunity to help more people stay cancer free after treatment, live well and survive breast cancer.”
Kristian Helin, chief executive of the Institute of Cancer Research, London, said: “This is a disappointing decision that will deny people with hereditary breast cancer access to personalized treatment that can improve their survival and help them stay cancer-free in the long term.’
soundhealthandlastingwealth
This post first appeared on انا اي٠| AnaEve انا اي٠عالمك ا, please read the originial post: here